読み込み中
NASDAQHealthcareMedical - Pharmaceuticals
最新データ
$3.76
−$0.10 · -2.59%
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.
前日終値
$3.76
−$0.10 · -2.59%
日中の時刻はETです。市場データは遅延する場合があります。
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.
日中レンジ
現在 $3.76
52週レンジ
現在 $3.76
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
10
著しい割高
センチメント
58
まちまち
リスク
91
極めて高いリスク
モメンタム
35
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.
日中レンジ
現在 $3.76
52週レンジ
現在 $3.76
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 43.16万 USD | 13.66万 USD | 136.38万 USD | 1025.02万 USD | 988.94万 USD |
| 売上原価 | 10.01万 USD | 13.06万 USD | 131.48万 USD | 473.09万 USD | 514.35万 USD |
| 粗利益 | 33.15万 USD | 6005 USD | 4.9万 USD | 551.93万 USD | 474.6万 USD |
| 研究開発 | 195.63万 USD | 223.67万 USD | 10.03万 USD | 99.32万 USD | 89.97万 USD |
| 販売・一般管理 | 1452.27万 USD | 1205.4万 USD | 444.55万 USD | 656.68万 USD | 753.58万 USD |
| 営業費用 | 1657.63万 USD | 1470.7万 USD | 444.55万 USD | 843.52万 USD | 1003.83万 USD |
| 受取利息 | 30.27万 USD | 13.53万 USD | 4198 USD | 2.1万 USD | — |
| 支払利息 | 408.32万 USD | 133.56万 USD | 114.32万 USD | 33.62万 USD | 2.36万 USD |
| 減価償却費と償却費 | 49.18万 USD | 5.34万 USD | 104.98万 USD | 19.47万 USD | 13.89万 USD |
| 営業利益 | −1624.48万 USD | −1470.1万 USD | −439.65万 USD | −291.6万 USD | −529.23万 USD |
| 純利益 | −4151.23万 USD | 906.58万 USD | −1784.36万 USD | −347.21万 USD | −531.59万 USD |
会社概要が更新されました 2026年10月11日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
